SEC investigating Illumina over acquisition of cancer test developer Grail

  • 📰 CNBC
  • ⏱ Reading Time:
  • 7 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 72%

Business News News

Business Business Latest News,Business Business Headlines

Illumina's acquisition of cancer test developer Grail has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

Last month, the SEC informed Illumina about the probe and requested documents and communications related to the. The agency also asked for statements and disclosures about the "conduct and compensation" of certain members of both Illumina and Grail's management, according to the filing.

Illumina's Grail deal has also faced heavy scrutiny from antitrust regulators in the U.S. and European Union.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in BUSİNESS

Business Business Latest News, Business Business Headlines